

Step Therapy Criteria

ATYPICALS

Products Affected

Step 2:

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL

Details

Criteria	Claim will pay automatically for Fanapt or Lybalvi if enrollee has a paid for at least a 1 day supply of 2 generic formulary agents in the past 365 days. Otherwise, Fanapt or Lybalvi requires a step therapy exception request indicating: (1) diagnosis that is not covered by 2 generic formulary agents, OR (2) history of inadequate treatment response with 2 generic formulary agents, OR (3) history of adverse event with 2 generic formulary agents, OR (4) 2 generic formulary agents are contraindicated.
----------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Formulary IDs: 24460, 24461, 24462, Version 16

Last Updated: 11/24/2024

Effective: 12/01/2024

Y0144_STCRIT24_C

RYTARY

Products Affected

Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 day supply of any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone OR (2) history of adverse event with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone, OR (3) any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone is contraindicated.
----------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Formulary IDs: 24460, 24461, 24462, Version 16
Last Updated: 11/24/2024
Effective: 12/01/2024
Y0144_STCRIT24_C

Index

F

FANAPT TABLET 1 MG ORAL	1
FANAPT TABLET 10 MG ORAL	1
FANAPT TABLET 12 MG ORAL	1
FANAPT TABLET 2 MG ORAL	1
FANAPT TABLET 4 MG ORAL	1
FANAPT TABLET 6 MG ORAL	1
FANAPT TABLET 8 MG ORAL	1
FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL	1

L

LYBALVI TABLET 10-10 MG ORAL	1
------------------------------------	---

LYBALVI TABLET 15-10 MG ORAL.....	1
LYBALVI TABLET 20-10 MG ORAL.....	1
LYBALVI TABLET 5-10 MG ORAL.....	1

R

RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL.....	2
RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL.....	2
RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL.....	2
RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL.....	2